CA Patent

CA2801066C — Compositions and methods directed to treating liver fibrosis

Assigned to Alnylam Pharmaceuticals Inc · Expires 2021-02-09 · 5y expired

What this patent protects

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-ß, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-ß, and SMAD2/3.

USPTO Abstract

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-ß, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-ß, and SMAD2/3.

Drugs covered by this patent

Patent Metadata

Patent number
CA2801066C
Jurisdiction
CA
Classification
—
Expires
2021-02-09
Drug substance claim
No
Drug product claim
No
Assignee
Alnylam Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.